Cipla acquires monoclonal antibodies maker Mabpharm
Mabpharm, a manufacturer of monoclonal antibodies for treatment of cancer and auto-immune diseases, will now become a wholly-owned subsidiary of Cipla
 "Cipla acquires monoclonal antibodies maker Mabpharm")
To further consolidate its position in biosimilars market, Cipla Ltd has taken over Mabpharm Private Limited, in which it was holding 25% stake. Cipla Ltd has informed BSE that Meditab Specialities Private Limited, a wholly owned subsidiary of the company, has acquired 75% stake in Mabpharm.
Consequent to the acquisition of the aforesaid stake, Mabpharm has now become a wholly-owned subsidiary of Cipla. Mabpharm is inter alia engaged in development of monoclonal antibodies for treatment of cancer and auto-immune diseases.
Consequent to the acquisition of the aforesaid stake, Mabpharm has now become a wholly-owned subsidiary of Cipla. Mabpharm is inter alia engaged in development of monoclonal antibodies for treatment of cancer and auto-immune diseases.